AKR1B10 has been shown to increase FAO in metastatic breast cancer,[43] and the inhibition of AKR1C1/2 can sensitize platinum‐resistant ovarian cancer toward carboplatin.[44]. Here, AKR1B10 is linked to ovarian cancer.